From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
Agent
Hospital
Dermatologist’s private office
GP’s private office
Adalimumab
6
5
2
Etanercept
Infliximab
0
Ustekinumab
4
1